RET FUSION-POSITIVE SOLID TUMOR
Clinical trials for RET FUSION-POSITIVE SOLID TUMOR explained in plain language.
Never miss a new study
Get alerted when new RET FUSION-POSITIVE SOLID TUMOR trials appear
Sign up with your email to follow new studies for RET FUSION-POSITIVE SOLID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets rare cancer drivers in chinese patients
Disease control OngoingThis phase 2 study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with specific RET gene changes. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and d…
Matched conditions: RET FUSION-POSITIVE SOLID TUMOR
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill shows promise against Hard-to-Treat RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…
Matched conditions: RET FUSION-POSITIVE SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC